Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR

European Journal of Heart Failure

Volumn 12, Issue 6, 2010, Pages 623-629

  Cleland, John G F ^a   Coletta, Alison P ^a   Buga, Laszlo ^a   Ahmed, Daniyal ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; LOOP DIURETIC AGENT; NATEGLINIDE; PLACEBO; TORASEMIDE; VALSARTAN;

ACUTE HEART FAILURE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER; CATHETER ABLATION; CONFERENCE PAPER; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CRYOABLATION; DEFIBRILLATOR; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOVASCULAR SURGERY; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUNG VEIN OBSTRUCTION; MEDICAL EDUCATION; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; NERVE PARALYSIS; PHRENIC NERVE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED;

EID: 77952977869     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq083     Document Type: Conference Paper

References (42)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
2. Hassleblad V, Stough WG, Shah MR, Lokhngina Y, O'Connor CM, Califf RM, Adams KF. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069.
3. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004;CD003178.
4. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary oedema. N Eng J Med 2008;359:142-151.
5. Constanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Has GJ, Anderson AS, Schollmeyer MP, Sobotka PA;, UNLOAD Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49: 675-683.
6. Seed A, Gardner R, McMurray J, Hillier C, Murdoch D, MacFayden R, Bobillier A, Mann J, McDonagh T. Nuerohormonal effects of the new orally active renin inhibitor, aliskiren in chronic heart failure. Eur J Heart Fail 2007;9:1120-1127.
7. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003;3:389-394.
8. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Mainsty CH, Mayet J, Francis DP. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009;95:56-62.
9. The ACCORD study group. Effects of intensive blood pressure control in type II diabetes mellitus. N Eng J Med 2010;362:1575-1585.
10. van Veldhuisen DJ, Maass AH, Priori SG, Stolt P, van Gelder IC, Dickstein K, Swedberg K. Implementation of device therapy (cardiac resynchronisation therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11: 1143-1151.
11. Braunschweig F, Ford I, Conrads V, Cowie MR, Jondeau G, Kauzner J, Lunati M, Munoz Aguilera R, Man Yu C, Marijianowski M, Borgreffe M, van Veldhuisen DJ;, DOT-HF Steering Committee, Investigators. Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF). Eur J Heart Fail 2008;10:970-1916
12. Crossley G, Boyle A, Vitense H, Sherfesee L, Mead RH. Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the clinical evaluation of remote notification to reduce time to clinical decision (CONNECT) study. Am Heart J 2008;156:840-846.
13. Stanley AW, Athanasuleas CL, Buckberg GD, RESTORE Group. Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. Heart Fail Rev 2004;9: 241-254.
14. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, for the STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Eng J Med 2009;360:1705-1717.
15. Cleland JGF, Coletta AP, Clark AL, Cullington D. Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 2009;11:622-630.
16. Di Donato M, Castelvecchio S, Menicanti L. End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated car-diomyopathy. Eur J Heart Fail 2010;12:375-381.
17. Cleland JG, Freemantle N, Ball SG, Bonser RS, Camici P, Chattopadhyay S, Dutka D, Eastaugh J, Hampton J, Large S, Norell M, Pennell DJ, Pepper J, Sanda S, Senior R, Smith D. The heart failure revascularisation trial (HEART): rationale, design and methodology. Eur J Heart Fail 2003;5:295-303.
18. Coletta AP, Cleland JGF, Cullington D, Clark AL. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 2008;10:917-920.
19. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005;26:1303-1308.
20. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009;11:676-683.
21. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Rossillo A, Di Biase L, Schweikert RA, Saliba V, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A. The risk of throm-boembolism and need for oral anticoagulants after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-743.
22. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Erdmann E. Effect of cardiac resynchronisation on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25.
23. Shelton RJ, Clark AL, Cleland JGF. The atrial fibrillation paradox of heart failure. Congest Heart Fail 2010;16:3-9.
24. Coletta A, Thackray S, Nikitin N, Cleland JGF. Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial, and HARDBALL. Eur J Heart Fail 2002;4:381-388.
25. Van Gelder IC, Groenvald HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, Hilledge HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, van Veldhuisen DJ, Van Den Berg MP, for the RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Eng J Med 2010;362: 1363-1373.
26. Cleland JGF, Shelton R, Nikitin N, Ford S, Frison L, Grind M. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of xime-lagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail 2007;9:730-739.
27. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R;, BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
28. Cleland JG, Cullington D. Digoxin: quo vadis? Circ Heart Fail 2009;2:81-85.
29. van Veldhuisen DJ, Aass H, El Allaf D, Dunselman PH, Gullestad L, Halinen M, Kjekshus J, Ohlsson L, Wedel H, Wikstrand J;, MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail 2006;8:539-546.
30. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhen-Grandjean M, Pochmalicki G, Dargie H. Hearta rate and cardiac rhythm relationships with biso-prolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001;103: 1428-1433.
31. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US carvedilol heart failure trials program. Am Heart J 2001;142: 498-501.
32. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure. J Am Coll Cardiol 2003;42:1944-1951.
33. Huikuri HV, Raatikainen MJP, Joergensen RM, Hartikainen J, Virtanen V, Boland J, Anttonen O, Hoest N, Boersma LVA, Platou ES, Meisser MD, Bloch-Thomsen PE;, for the CARISMA study group. Prediction of fatal or near fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocar-dial infarction. Eur Heart J 2009;30:689-698.
34. Agricola E, Ielasi A, Oppizzi M, Faggiano P, Ferri L, Calabrese A, Vizzardi E, Alfiero O, Mardgonato A. Long-term prognosis of medically treated patients with functional mitral valve regurgitation and left ventricular dysfunction. Eur J Heart Fail 2009;11:581-587.
35. Bursi F, Barbieri A, Grigioni F, Reggianini L, Zanasi V, Leuzzi C, Ricci C, Piovaccari G, Branzi A, Modena MG. Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 2010;12:382-388.
36. Clark AL, Alamgir MF, Nair RK, Thackray ST. Percutaneous surgery for mitral valve disease. Heart 2009;95:1850.
37. Harjola VP, Follath F, Nieminen M, Butsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L. Characteristics, outcomes and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12:239-248.
38. Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J Card Fail 2009;15:305-309.
39. Macdonald MR, Petrie MC, Varyani F, Ostergren J, Michelsen EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer M, McMurray JJ;, CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the CHARM programme. Eur Heart J 2008;29:1377-1385.
40. The NAVIGATOR study group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Eng J Med 2010;362:1463-1476.
41. The NAVIGATOR study group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Eng J Med 2010;362:1477-1490.
42. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of haemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009;54: 422-428.